Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264808 · ClinicalTrials.gov registry record
Developmental Outcomes
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 21
- Enrollment target
NCT02264808: Completed study, sponsored by University of Florida.
NCT02264808 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02264808 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Determine whether the concentrations of UCH-L1 and GFAP measured in umbilical cord blood and in blood 0-6 hours postnatal accurately predict the extent of neurodevelopmental deficits and/or death at 18-20 months.
Primary Outcome
Compare Developmental Outcomes to HIE Biomarker concentrations at birth
Interventions
- OTHER Developmental Outcomes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-12-03 |
What the finished NCT02264808 record still lists
NCT02264808 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Developmental Outcomes is the first listed.
NCT02264808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02264808 about?
NCT02264808 is a clinical study titled "Developmental Outcomes". Determine whether the concentrations of UCH-L1 and GFAP measured in umbilical cord blood and in blood 0-6 hours postnatal accurately predict the extent of neurodevelopmental deficits and/or death at 18-20 months.
What is the current status of trial NCT02264808?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2014-11. Estimated completion is 2018-12-03.
What interventions are being tested in trial NCT02264808?
The interventions under investigation include: Developmental Outcomes (OTHER).
Who is sponsoring clinical trial NCT02264808?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia